Form 8-K - Current report:
SEC Accession No. 0001104659-21-103213
Filing Date
2021-08-11
Accepted
2021-08-11 08:32:34
Documents
14
Period of Report
2021-08-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2124796d1_8k.htm   iXBRL 8-K 31549
2 EXHIBIT 99.1 tm2124796d1_ex99-1.htm EX-99.1 19073
6 GRAPHIC tm2124796d1_ex99-img001.jpg GRAPHIC 15285
  Complete submission text file 0001104659-21-103213.txt   254822

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20210811.xsd EX-101.SCH 3194
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20210811_lab.xml EX-101.LAB 34593
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20210811_pre.xml EX-101.PRE 22716
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2124796d1_8k_htm.xml XML 3715
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 211162090
SIC: 2834 Pharmaceutical Preparations